What soul torture does SABCS heavyweight TOP5 leave behind?

I. Can patients with positive lymph nodes and low risk be exempted from chemotherapy? The RxPONDER study, reported on SABCS, aims to test whether the Oncotype21 gene test can be used to determine the prognostic assessment of 1-3 positive HR-plus and HER2-endocrine-reactive patients in the lymph nodes.
, the Relapse Risk Score (RS) score did not predict the efficacy of chemotherapy in the general population.
there was no significant difference in 5 years of iDFS ≤ 25 patients, whether chemotherapy or not.
, regardless of RS, pre-menomoth patients benefited significantly from chemotherapy, with an absolute benefit of 5.2%, while post-menoanth patients did not benefit from chemotherapy.
This suggests that early post-menoanthe breast cancer in N1-3, RS<25 may be exempt from chemotherapy, while pre-menoantherapy may still require chemotherapy on the basis of endocrine therapy.
(Source: SABCS 2020, same as 2020) From previous studies, whether it is 21 genes, 70 gene testing, the dominant population are post-menotinal patients.
the benefits of receiving combination chemotherapy in patients with low pre menoporal risk, can the effects of ovarian function inhibition be explained? How do you guide clinical decision-making in patients with inconsistent RS and traditional clinical pathological characteristics? How to solve the limitation of the non-high consistency of multi-gene detection technology in the future? Second, early breast cancer-assisted treatment, CDK inhibitors watershed? The SABCS Conference reported the results of the third interim analysis of the monarchE study.
increased the number of follow-up and 67 iDFS events by 3.6 months compared to the second interim analysis, and increased the treatment analysis of Abesili combined with assisted endocrinology in the Ki-67 high-expression population.
results show that Abersilly's combined iDFS continues to provide significant statistical and clinical benefits, and that it benefits more in the Ki-67 high expression population (≥20%) and reduces the risk of recurrence by 30.9%, with an absolute benefit rate of 4.5% over two years.
, however, he plus, HER2-early breast cancer has a long-term risk of recurrence, can the benefits of Abersili in the MonarchE study withstand longer follow-up tests? The PENELOPE-B III study included a group of 1,250 patients with early breast cancer after HR-/HER2-surgery, who were randomized to receive 1 year of combined endocrine therapy with a pyrethroid or placebo, with the main endpoint being iDFS.
Although the survival curve was briefly separated over a two-year period, the three-year iDFS was 81.2% vs. 77.7% (HR-0.93, p-0.525) at 43 months of medium follow-up, and there was no statistical difference;
16.6 percent and 42.2 percent of patients in the MonarchE and PALAS studies had treatment interruptions, respectively, after the view was expressed that differences in outcomes might be related to drug compliance.
the PENELOPE-B study had a drug-stopping rate of 19.5%, how do you understand this result? What are the risk levels of the group? Biological characteristics? Different efficacy for primary endocrine therapy for drug-resistant patients? Three, three Yin breast cancer first-line treatment competition white heating a month ago, K drug and chemotherapy in combination with fda accelerated approval for tumor expression PD-L1 (CPS) ≥10) non-removable local recurrence or metastasis triple negative breast cancer (TNBC) patients, MSD in the field of third-negative breast cancer first-line treatment officially declared war on Roche.
the SABCS conference, the researchers presented keyNOTE-355 research PFS update results and key secondary endpoint results.
subgroup analysis showed that any of the three chemotherapy options combined with Pabliju monoantigens improved PFS in metastasis TNBC patients.
orR, DCR, and DOR were higher in patients with higher expression of PD-L1.
results further support the use of Paboli juju monotherapy as a first-line treatment for metastasis TNBC patients.
Phase III study of mTNBC's first-line immuno-combined chemotherapy, can the PFS extension currently observed by KEYNOTE-355 translate into OS benefits? Strong enemy soldiers in the city, regret the fold of the IMpassion 131 study, why the negative results, is still an unsolt mystery.
What choice should clinicians make for the
Atili Pearl monoantigen-combined albumin solution PK Paboli single-anti-albumin yew alcohol, yew alcohol, and GC solution (Gisithamin/Capra) clinicians? Fourth, heavy ADC drug SG, efficacy benefits are not affected by Trup-2 expression? Sacituzumab Govitecan (SG) is the world's first antibody-coupled drug to target TRAP-2.
ASCENT study is the first Phase III study in patients with metastasis triple-yin breast cancer, SG has significant benefits from PFS, OS, or ORR compared to the single-drug standard chemotherapy (TPC) chosen by doctors, and is well-to-resistant and has controlled safety.
conference reported on the relationship between Trap-2 expression and embryo BRCA1/2 mutation status, two biomarkers and the efficacy of SG drugs.
study found that in metastasis TNBC, regardless of Trtp-2 expression level, regardless of whether BRCA1/2 has embryonic mutations, the SG group had clinical benefits over the TPC group.
considering the small sample size of the subgroup analysis, care should be taken when interpreting the data.
, IPATunity 130 fold, AKT inhibitors in the late TNBC has a place? Ipatasertib is an ATP competitive inhibitor of AKT, licensed by Roche from Arry.
Phase III clinical study Ipatunity-130 aims to evaluate the efficacy and safety of the late TNBC in the first-line treatment of Ipatunity-130 ipatasertib combined with yew alcohol for PIC3CA/AKT1/PTEN mutations.
was very different from phase II study LOTUS, where the IPATunity130 study did not differ in median PFS between groups, including pre-defined subgroups (whether new complementary therapy, geography, tumor pathline status in the past), and missed the main study endpoint.
OS is not yet mature (20% of patients die).
failure a result of drugs, research design, or biomarker selection, or something else? May AKT promote DNA repair and checkpoint activation, triggering drug-resistant secondary subtype mutations? Heterogeneity of people with triple negative breast cancer? Are longer-term follow-up likely to observe OS benefits? Research analysis is ongoing to assess biomarkers of potential benefits.
。